Prime Minister's Program for Prevention & Control of Hepatitis

Govt. of Khyber Pakhtunkhwa Health Department, Khyber Pakhtunkhwa, Peshawai

Tentative Zero Draft Comparative Statement (Technical score + financial Score (100)

For the procurement of Hepatitis B & C medicine & biological 2019-20.

- All concerned to please note in the public interest that:

 1. This list is a draft tentative comparative statement to serve the only purpose of ensuring more transparency and equity in the bidding process by providing equal opportunities to all concerned bidders to have access to information related to their bids and fair competition; and
- 2. This list will be kept on this website till 4.00 p.m. on 15 May. 2020; and

- 3. This list is not an approved legal document to have any authority or weightage or value for any legal proceedings in any court of law or any other forum; and
 4. This list is being shared to eliminate the possibility of any error in terms of figures or words related to quoted items and the prices offered in the bids; and
 5. It is stressed to please note that this list is in no way a final document to be used as an evidence or argument for selection of products for rate contracting from the lowest bidder or
- award or justification of supply contract / order to the selected bidder by the procuring agency; and
 6. All possible efforts have been made to reduce human errors and omissions but still inadvertent errors and omissions may possibly be expected in this list. All the bidders participating in this bidding competition are expected and requested to thoroughly examine this comparative statement and point out any error or omission in terms of quoted price, unit price, names,
- strength, quantity, financial and total marks obtained, etc. of products or any other details which have wrongly been entered into this list.

 7. Any feedback related to errors and omissions must reach the office of Provincial Coordinator PM's Program for Prevention & Control of Hepatitis at Directorate General Health Services, Warsak Road, Peshawar not later than 4.00 p.m. on 15 May, 2020, in written form duly signed and attested by the responsible relevant person of the bidding entity. The feedback may also be communicated through email, at hepatitis.kp@gmail.com
- 8. This list is only meant to rectify / correct the mistakes, if any that might have occurred during the data entry process for the already submitted financial bids to facilitate final bidding competition to be held shortly by the Selection & Rate Contracting Committee of PM's Program. Therefore, no new or revised data in technical score, information, price, claim, explanation, etc. will be entertained for entering into and / or in any way affecting and / or manipulating the final list for the bidding competition; and 9. All the bidders are welcome to comment on any deficiencies etc. in this list as related to their own quoted items only and not on their competitors and / or any other bidders in this list
- 10. Any comments, feedback etc. received after the above mentioned cutoff time and date (Para-7 above) will not be considered and the so finalized list will be placed before the Selection & Rate Contracting Committee, for finalizing the competition in the best public interest.

 11. The Selection and Rate contracting committee, at its discretion as per KPPRA rules may decide select or otherwise any item mentioned in this comparative statement for the current

		Tent	Name of Firm	ent of Hepatiti	s Control Prog	ram Medio	ine/Dru	ıgs 2019-2	20		
S. No.	Product General Information						Financial Evaluation				
						Total Technical Score	Quoted Unit Price	Lowest Quoted Price among the qualified bids for particular item	Maximum Allocable Price Score	Score of financial bid	Final Grand Total of Scores
	S#	Name of Firm	Generic Name of Item	Dosage Form with Strength	Trade Name	70	0	0	30	30	100
		•	•		b. Tenofovir						
		Macter Pharma	Tenofovir	300mg	Vireof	44	14.92	14.92	30	30.000	74.000
		Getz Pharma	Tenofovir	300mg	Tenofo-B	57	15.40	14.92	30	29.065	86.065
		Searle Pharma	Tenofovir	Ü		42		14.92	30		
		Caliph Pharma	Tenofovir	300mg	Sefovir		17.50 Jon-Respo		30	25.577	67.577
	1	Campii i ilaiiila	1011010111	Tab.Sofosbuvi	r + Ribavirin	•	гаторо				
		Feroz Sons	Sofosbuvir	400mg	Savera	41	55.36	55.36	30	30	
		Searle Pharma	Sofosbuvir	400mg	Sobvi	37	64.29	55.36	30	25.833	62.833
		Getz Pharma	Sofosbuvir	400mg	Sofiget	51	74.82	55.36	30	22.197	73.197
		Genix Pharma	Sofosbuvir	400mg	Sofos	38	68.00	55.36	30	24.424	62.424
		Mactor Pharma	Sofosbuvir	400mg	Sofomac	43	64.00	55.36	30	25.950	68.950
		AGP Pharma Sofosbuvir 400mg Non-Responsvie									
			Hep-B vaccine alor	ng with D. Syringe	(along with D.Syri	nge free of cos	st)				
		Hoffman	Hep-B vaccine (along with 1cc, Syringe free of cost)	0.5mL (Birth Dose)	Hepatitis B vaccine(rDNA)	55	170	170	30	30	85.000
		Hoffman	Hep-B vaccine (along with 1cc, Syringe free of cost)	1mL (Birth Dose)	Hepatitis B vaccine(rDNA)	55	225	225	30	30	85.000
		Amson Vaccine & Pharma	Hep-B vaccine (along with 1cc, Syringe free of cost)	0.5mL (Birth Dose)	Amvex-B		Non-Responsvie				
		Amson Vaccine & Pharma	Hep-B vaccine (along with 1cc, Syringe free of cost)	1mL	Amvex-B		ivon-kesponsvie				
				Tab. Dec	latasvir						
		Getz Pharma	Declatasvir	60mg	Declaget	51	9.11	7.90	30	26.015	77.02
		Searle Pharma	Declatasvir	60mg	Dektovi	27	12.93	7.90	30	18.329	45.33
		Mactor Pharma	Declatasvir	60mg	Maclinza	48	9.85	7.90	30	24.061	72.06
		Feroz Sons	Declatasvir	60mg	Daklana	41	9.10	7.90	30	26.044	67.04
	ļ	Genix Pharma	Declatasvir	60mg	Daclit	38	7.90	7.90	30	30.000	68.00
		AGP Pharma	Declatasvir	60mg	Declar			Non-R	Responsive		
				Tab. Velpa+							
		Sami Pharma	Vepla+Sofos	400mg+100mg	Ocvir-V	47	182.14	182.14	30	30.000	77.00
	ļ	Mactor Pharma	Vepla+Sofos	400+100mg	Maclusa	43	197.86	182.14	30	27.616	70.62
	ļ	Searle Pharma	Vepla+Sofos	400mg+100mg	Sovela	37	200.00	182.14	30	27.321	64.32
	ļ	Genix Pharma	Vepla+Sofos	400mg+100mg	Velso	28	529.00	182.14	30	10.329	38.33
	1	Getz Pharma	Velpa+Sofos	400+100mg	Velpaget	46	182.50	182.14	30	29.941	75.94